Buchumschlag

Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation

Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition. In most cases, the recurrent tumor is presented with extrahepatic spread. Therefore, systemic treatment with sorafenib has to be assessed. Because of a plethora of possible drug interaction...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pfeiffenberger, Jan (VerfasserIn) , Koschny, Ronald (VerfasserIn) , Hoffmann, Katrin (VerfasserIn) , Mehrabi, Arianeb (VerfasserIn) , Schmitz, Anne (VerfasserIn) , Radeleff, Boris (VerfasserIn) , Stremmel, Wolfgang (VerfasserIn) , Schemmer, Peter (VerfasserIn) , Ganten, Tom M. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 4 October 2013
In: Langenbeck's archives of surgery
Year: 2013, Jahrgang: 398, Heft: 8, Pages: 1123-1128
ISSN:1435-2451
DOI:10.1007/s00423-013-1114-1
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s00423-013-1114-1
Volltext
Verfasserangaben:Jan Pfeiffenberger, Ronald Koschny, Katrin Hoffmann, Arianeb Mehrabi, Anne Schmitz, Boris Radeleff, Wolfgang Stremmel, Peter Schemmer, Tom M. Ganten
Beschreibung
Zusammenfassung:Recurrent hepatocellular carcinoma (HCC) after liver transplantation (LT) is a rare but challenging condition. In most cases, the recurrent tumor is presented with extrahepatic spread. Therefore, systemic treatment with sorafenib has to be assessed. Because of a plethora of possible drug interactions, e.g., with immunosuppressant or anti-infective therapy, safety and feasibility of sorafenib treatment requires special attention.
Beschreibung:Gesehen am 20.01.2022
Beschreibung:Online Resource
ISSN:1435-2451
DOI:10.1007/s00423-013-1114-1

Ähnliche Einträge